$747.9 M

PHAT Mkt cap, 31-Mar-2020
Phathom Pharmaceuticals Net income (FY, 2019)-255.1 M
Phathom Pharmaceuticals EBIT (FY, 2019)-106.2 M
Phathom Pharmaceuticals Cash, 31-Dec-2019243.8 M
Phathom Pharmaceuticals EV527 M

Phathom Pharmaceuticals Income Statement

Annual

USDFY, 2018FY, 2019

R&D expense

20.0k20.4m

General and administrative expense

1.2m6.9m

Operating expense total

2.5m27.3m

EBIT

(1.2m)(106.2m)

Interest expense

13.0k4.2m

Interest income

1.1m

Income tax expense

Net Income

(1.3m)(255.1m)

Quarterly

USDQ3, 2019

R&D expense

4.5m

General and administrative expense

1.8m

Operating expense total

6.3m

EBIT

(6.3m)

Interest expense

2.0m

Interest income

429.0k

Net Income

(68.1m)

Phathom Pharmaceuticals Balance Sheet

Annual

USDFY, 2018FY, 2019

Cash

879.0k243.8m

Prepaid Expenses

11.8m

Current Assets

902.0k255.6m

PP&E

463.0k

Total Assets

902.0k257.2m

Accounts Payable

55.0k699.0k

Short-term debt

156.0k

Current Liabilities

2.2m3.7m

Long-term debt

22.8m

Total Debt

22.9m

Total Liabilities

2.2m29.2m

Common Stock

2.0k

Additional Paid-in Capital

2.0k484.4m

Retained Earnings

(1.3m)(256.4m)

Total Equity

(1.3m)228.0m

Financial Leverage

-0.7 x1.1 x

Quarterly

USDQ2, 2019Q3, 2019

Cash

82.9m74.5m

Prepaid Expenses

3.2m

Current Assets

84.5m77.7m

PP&E

40.0k

Total Assets

84.9m79.7m

Accounts Payable

450.0k439.0k

Current Liabilities

144.8m207.5m

Long-term debt

22.4m22.6m

Total Debt

22.4m22.6m

Total Liabilities

169.3m232.2m

Common Stock

11.9m

Additional Paid-in Capital

5.9m6.0m

Retained Earnings

(90.3m)(158.4m)

Total Equity

(84.4m)(152.5m)

Financial Leverage

-1 x-0.5 x

Phathom Pharmaceuticals Cash Flow

Annual

USDFY, 2018FY, 2019

Net Income

(1.3m)(255.1m)

Depreciation and Amortization

8.0k

Accounts Payable

2.3m

Cash From Operating Activities

(1.0m)(36.5m)

Purchases of PP&E

(132.0k)

Cash From Investing Activities

(25.2m)

Cash From Financing Activities

1.9m304.6m

Net Change in Cash

879.0k242.9m

Interest Paid

1.0m

Quarterly

USDQ2, 2018Q2, 2019Q3, 2019

Net Income

(514.0k)(89.0m)(157.1m)

Depreciation and Amortization

2.0k

Accounts Payable

1.6m

Cash From Operating Activities

(452.0k)(6.0m)(13.1m)

Purchases of PP&E

(26.0k)

Cash From Investing Activities

(25.1m)(25.1m)

Cash From Financing Activities

552.0k113.2m111.9m

Net Change in Cash

100.0k82.0m73.6m

Interest Paid

86.0k549.0k

Phathom Pharmaceuticals Ratios

USDY, 2019

EV/EBIT

-5 x

EV/CFO

-14.4 x

Financial Leverage

1.1 x

Phathom Pharmaceuticals Operating Metrics

Oct, 2019

Drugs in Development

1

Phase III Trials Products

1